GTCbio: 4th Modern Drug Discovery & Development Summit - Plenary Keynote Address by Dr. Keith James from Pfizer
SVP and Site Head of Pfizer La Jolla announced as Plenary Keynote Speaker for
the 4thModern Drug Discovery & Development Summit (M3D).
FOR IMMEDIATE RELEASE
June 11, 2008
SVP and Site Head of Pfizer La Jolla to Give Plenary Keynote Address at 4th
Modern Drug Discovery & Development Summit (Oct. 15-17, 2008 – San Diego, CA)
MONROVIA, CA – Dr. Keith James, Senior Vice President and Site Head of Pfizer
La Jolla will present at the Plenary Keynote session at GTCbio’s 4th Modern
Drug Discovery and Development Summit on October 15-17, 2008 at the Hilton
La Jolla Torrey Pines in La Jolla, CA.
Dr. James will speak on the challenges & opportunities of driving global R&D
performance. His presentation will explore approaches taken at Pfizer to transform
its R&D organization, encompassing changes in all these dimensions. It will
also highlight the progress made to date in terms of hard success measures
and the outlook for the future.
Dr. James will discuss ideal business models where organizational, therapeutic,
technology, internal and external resources are all considered, explaining
which dimensions offers the largest potential opportunity for transformation
of the pharma R&D model to deliver innovative new therapies cost-effectively
and how much progress is being made in pursuit of these changes.
The 4th Modern Drug Discovery & Development Summit features over 150 speakers
participating in 6 concurrent conferences, 6 mini sessions and 3 short symposia.
Other plenary speakers at the keynote session include John Doll, Commissioner
of Patents at the US Patent & Trademark Office, David Nicholson, SVP of Global
Project Management at Schering Plough, Ashraf Hanna, VP of Business Development
at Genentech and Sandy Macrae, VP of Business Development at GlaxoSmithKline.
The 6 tracks will cover Biological Therapeutics, Translational Medicine, Drug
Design & Lead Optimization, Emerging Targets &, Pharmacokinetics & Pharmacodynamics
and Partnering, Licensing & Outsourcing. For more information, visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government organizations,
and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held
company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
Keywords,
drug, drugs, drug discovery, drug development, discovery and development, m3d,
modern drug, pharmacokinetics, pharmacodynamics, pharmacogenomics, translational
medicine, metabolic, stem cell, stem cell research, stem cells, regenerative
medicine, antibodies, CNS, nervous system, partnering, licensing, deal-making,
outsourcing, alliance management, John doll, David Nicholson, Ashraf Hanna,
Sandy Macrae, United States Patent & Trademark office, keith james, drug delivery,
biomedical, life sciences, pharmaceutical, pharma, patents, biotech, model
organisms, mouse models, cancer, chemistry, epigenetic, pharmacology, pharmacogenetics,
molecular biology, biological therapeutics, biologics, biomarker
